Details for Patent: 7,763,615

Which drugs does patent 7,763,615 protect, and when does it expire?

Patent 7,763,615 protects ZEPZELCA and is included in one NDA.

This patent has thirty-two patent family members in twenty-three countries.

Summary for Patent: 7,763,615

Title:	Ecteinascidin analogs for use as antitumour agents
Abstract:	Derivatives of ecteinascidin 736 of general formula (I) wherein the groups R1, R2, R3, R4 and R5 are each independently selected from the group consisting of H, OH, OR′, SH, SR′, SOR′, SO2R′, C(═O)R′, C(═O)OR′, NO2, NH2, NHR′, N(R′)2, NHC(O)R′, CN, halogen, ═O, substituted or unsubstituted C1-C25 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic; wherein X is independently selected of OR′, CN, (═O), or H; wherein each of the R′ groups is independently selected from the group consisting of H, OH, NO2, NH2, SH, CN, halogen, ═O, C(═O)H, C(═O)CH3, CO2H, substituted or unsubstituted C1-C25 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl; wherein m is 0, 1 or 2; and wherein n is 0, 1, 2, 3, or 4, and their use as antitumoral agent.
Inventor(s):	Pilar Gallego, Carmen Cuevas, Simon Munt, Ignacio Manzanares, Valentin Martinez
Assignee:	Pharmamar SA
Application Number:	US10/485,536
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,763,615
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,763,615

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes			Y	Y		MAINTENANCE TREATMENT OF ADULT PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) WHOSE DISEASE HAS NOT PROGRESSED AFTER FIRST-LINE INDUCTION THERAPY
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes			Y	Y		TREATMENT OF ADULT PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY.

Foreign Priority and PCT Information for Patent: 7,763,615

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0119243.4	Aug 7, 2001

PCT Information
PCT Filed	August 06, 2002	PCT Application Number:	PCT/GB02/03592
PCT Publication Date:	February 20, 2003	PCT Publication Number:	WO03/014127

International Family Members for US Patent 7,763,615

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	374777
Australia	2002313540
Canada	2455768
China	100334094
China	1564822